Business Context and Reporting Period
The filing is NeuroBo Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022; it does not identify the company as Metavia Inc. NeuroBo is a clinical-stage biotechnology company with no product revenue. Its primary programs are DA-1241 for NASH and type 2 diabetes and DA-1726 for NASH and obesity. Additional programs include ANA001, NB-01, NB-02, and Gemcabene.
Financial Highlights
| Metric | Three Months Ended September 30, 2022 | Nine Months Ended September 30, 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $0.6 million | $2.5 million |
| General and administrative expense | $2.5 million | $6.7 million |
| Total operating expenses | $3.1 million | $9.2 million |
| Net loss | $3.1 million | $9.3 million |
| Loss per share, basic and diluted | $3.50 | $10.45 |
| Cash used in operating activities | Not separately reported | $9.9 million |
At September 30, 2022, cash was $6.4 million, total assets were $7.6 million, total liabilities were $1.6 million, and stockholders’ equity was $5.9 million. The company reported no debt in the provided balance sheet. Its accumulated deficit was $91.1 million.
Material Changes Versus Prior Comparable Period
- For the quarter, R&D expense decreased $0.8 million to $0.6 million, primarily due to reduced ANA001 clinical-trial activity and drug manufacturing costs.
- For the nine-month period, R&D expense decreased $2.1 million to $2.5 million for similar reasons.
- General and administrative expense increased $0.5 million for both the quarter and nine-month period, primarily due to higher legal and professional fees and stock-based compensation.
- Quarterly net loss improved by $0.3 million, from $3.5 million to $3.1 million. Nine-month net loss improved by $1.4 million, from $10.7 million to $9.3 million.
- Cash declined $10.0 million during the first nine months, from $16.4 million at December 31, 2021 to $6.4 million at September 30, 2022.
- The company completed a one-for-thirty reverse stock split effective September 12, 2022; share and per-share information was retroactively adjusted.
Outlook, Risks, Contingencies, and Unusual Items
- ANA001 Phase 2 enrollment closed in July 2022 after 48 participants were enrolled; the trial moved to data analysis, with results expected in the fourth quarter of 2022.
- The company ceased development of NB-01 on its prior Phase 3 pathway and is evaluating orphan-drug and nutraceutical alternatives. NB-02 development and initial human trials were postponed.
- On September 14, 2022, NeuroBo entered a license agreement with Dong-A ST for DA-1241 and DA-1726. The agreement became effective November 8, 2022 and includes an upfront payment valued at $22.0 million in preferred stock, potential regulatory milestones of up to $178 million for DA-1726 and $138 million for DA-1241, commercial milestones, and single-digit royalties on net sales.
- After the reporting date, the company raised approximately $32.3 million in gross proceeds through a public offering and private placement. Management stated that liquidity was sufficient to fund operations for at least twelve months from the financial-statement issuance date, but additional funding will be required until revenue is generated.
- The company reported substantial doubt about its ability to continue as a going concern before considering the subsequent financing. It continues to incur losses and negative operating cash flows.
- COVID-19, geopolitical conditions, inflation, supply-chain constraints, clinical-trial execution, regulatory approval, competition, and patient enrollment remain material risks.
- Disclosure controls were not effective as of September 30, 2022 because of material weaknesses involving segregation of duties, wire transfers, journal-entry review, clinical-trial accrual review, and logical access to financial systems. Remediation was in progress.
- Potential obligations under license, merger, milestone, royalty, and contingent-value-rights arrangements were not accrued because achievement or payment was not considered probable. Legal proceedings were not expected to have a material adverse effect.
Investor Verification Points
- Confirm the issuer identity: the supplied filing is for NeuroBo Pharmaceuticals, Inc., not Metavia Inc.
- Verify the post-quarter-end public offering, Dong-A private placement, preferred-stock issuances, warrant terms, dilution, and resulting capitalization.
- Assess whether the stated twelve-month liquidity outlook remains adequate given the company’s expected development spending and continuing operating losses.
- Review ANA001 trial results and subsequent regulatory discussions, as well as development plans for DA-1241 and DA-1726.
- Evaluate the financial and governance consequences of the Dong-A transaction, including potential control upon conversion of preferred stock.
- Monitor remediation of the disclosed material weaknesses in internal control over financial reporting.